Denali Therapeutics (NASDAQ:DNLI) Announces Earnings Results, Beats Expectations By $0.08 EPS

Denali Therapeutics (NASDAQ:DNLI) announced its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.08, Zacks reports.

Denali Therapeutics Trading Down 1.5 %

Shares of DNLI stock opened at $18.60 on Friday. The company has a market capitalization of $2.68 billion, a P/E ratio of -6.74 and a beta of 1.43. The business’s 50 day moving average is $21.44 and its two-hundred day moving average is $24.63. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33.

Insider Activity

In related news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total value of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company’s stock, valued at $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock worth $973,442 over the last quarter. 7.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on DNLI shares. HC Wainwright boosted their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday. Jefferies Financial Group increased their target price on Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a report on Wednesday, January 15th. Finally, Baird R W raised Denali Therapeutics to a “strong-buy” rating in a report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.42.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.